Clinical Trials Logo
  1. Home
  2. Drug Hypersensitivity
  3. NCT00198419
  4. Details
NCT00198419 Clinical Trial

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

Drug Hypersensitivity Clinical Trial

Official title:
Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Open Label, Normal Volunteer Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00198419
Other study ID # ISTA-VIT-CS04
Secondary ID
Status Completed
Phase Phase 1
First received September 13, 2005
Last updated March 13, 2013
Start date March 2004
Est. completion date March 2004

Study information
Verified date March 2013
Source Bausch & Lomb Incorporated
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.

Recruitment information / eligibility
Status Completed
Enrollment 65
Est. completion date March 2004
Est. primary completion date March 2004
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Avoid disallowed meds throughout study

Exclusion Criteria:

- Known hypersensitivity to hyaluronidase and/or bee sting

- Atopic individuals assessed by med history

- Topical/systemic corticosteroids within 30 days

- Concurrent use of antihistamines or anti-inflammatory during study

- Active or chronic disease likely to affect immune function

- History of alcohol/drug abuse within 6 months

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

Intervention

Drug:
• Vitrase

Locations
Country Name City State
United States Solano Clinical Research (A Division of Dow Pharmaceutical Sciences) Davis California

Sponsors (1)
Lead Sponsor Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Hypersensitivity hypersensitivity to Vitrase following a single intradermal injection of 3 USP Units Vitrase 1-2 days No
See also
  Status Clinical Trial Phase
Completed NCT02839551 - Optimal Doses for Drug Provocation Tests to Beta-lactams N/A
Completed NCT02839811 - Medical Device for Drug Allergy Diagnosis N/A
Completed NCT02983630 - Allergy Testing of Patients Labeled as Penicillin Allergic N/A
Completed NCT00198458 - Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Phase 1
Recruiting NCT04330118 - Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Completed NCT04421638 - Cephalosporin Hypersensitivity
Recruiting NCT02031120 - Management of Drug Hypersensitivity in Children N/A
Completed NCT01276314 - Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions N/A
Terminated NCT00505648 - Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin) Phase 3
Completed NCT03158831 - Drug Challenges Without Prior Skin Testing Phase 1
Completed NCT03076749 - Predictive Models for Betalactam Allergy N/A
Active, not recruiting NCT06428162 - An Evaluation of Healthcare Providers' Adherence to Pharmacovigilance Practices in an African Community
Terminated NCT02844712 - Negative Predictive Value of Drug Provocation Tests to Beta-lactams N/A
Completed NCT03771118 - Drug Provocation Test (DPT) to Paracetamol
Completed NCT03743220 - Drug Provocation Test (DPT) to Non Steroidal Anti-inflammatory Drugs (NSAID)
Not yet recruiting NCT06406114 - Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Phase 2
Completed NCT05269082 - A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
Completed NCT04827602 - Drug Allergy Labels After Drug Allergy Investigation